ABSTRACT Previously we showed that atrial natriuretic factor (ANF) decreases cardiac cell volume by inhibiting ion uptake by Na+/K+/2CI-cotransport. Digital video microscopy was used to study the role of guanosine 3',5'-monophosphate (cGMP) in this process in rabbit ventricular myocytes. Each cell served as its own control, and relative cell volumes (volumetest/volumeco,trol) were determined. Exposure to 10 IxM 8-bromo-cGMP (8-Br-cGMP) reversibly decreased cell volume to 0.892 -0.007; the EDs0 was 0.77 +-0.33 tzM. Activating guanylate cyclase with 100 IxM sodium nitroprusside also decreased cell volume to 0.889 ---0.009. In contrast, 8-bromo-adenosine 3',5'-monophosphate (8-Br-AMP; 0.01-100 tzM) neither altered cell volume directly nor modified the response to 8-Br-cGMP. The idea that cGMP decreases cell volume by inhibiting Na+/K+/2C1-cotransport was tested by blocking the cotransporter with 10 I~M bumetanide (BUM) and removing the transported ions. After BUM treatment, 10 IxM 8-Br-cGMP failed to decrease cell volume. Replacement of Na ÷ with N-methyl-D-glucamine or C1-with methanesulfonate also prevented 8-Br-cGMP from shrinking cells. The data suggest that 8-Br-cGMP, like ANF, decreases ventricular cell volume by inhibiting Na+/K+/2C1-cotransport. Evidence that ANF modulates cell volume via cGMP was also obtained. Pretreatment with 10 IzM 8-Br-cGMP prevented the effect of 1 IzM ANF on cell volume, and ANF suppressed 8-Br-cGMP-induced cell shrinkage. Inhibiting guanylate cyclase with the quinolinedione LY83583 (10 tzM) diminished ANF-induced cell shrinkage, and inhibiting cGMP-specific phosphodiesterase with M&B22948 (Zaprihast; 100 IzM) amplified the volume decrease caused by a low dose of ANF (0.01 I~M) approximately fivefold. In contrast, neither 100 I~M 8-Br-cAMP nor 50 tzM forskolin affected the response to ANF. The effects of ANF, LY83583, and M&B29948 on cGMP levels in isolated ventricular myocytes were confirmed by 125I-cGMP radioimmunoassay. These data argue that ANF shrinks cardiac cells by increasing intracellular cGMP, thereby inhibiting Na+/K+/2C1-cotransport. Basal cGMP levels also appear to modulate cell volume.
INTRODUCTION
By moving ions inward across the plasma membrane, Na+/K +/2C1-cotransport plays an important role in regulating cell volume in a number of tissues (Eveloff and Warnock, 1987; Larson and Spring, 1987; MacKnight, 1987; O'Grady, Palfrey, and Field, 1987; Hoffman and Simonsen, 1989) . Na+/K+/2C1-cotransport has not been characterized fully in the heart. Nevertheless, intracellular ion activity and isotopic flux studies suggest that the cotransporter is present in rabbit ventricle (Baumgarten and Duncan, 1987) and cultured chick myocytes (Aiton, Chipperfield, Lamb, Ogden, and Simmons, 1981; Frelin, Chassande, and Lazdunski, 1986; Liu, Jacob, PiwnicaWorms, and Lieberman, 1987) , and measurements of cardiac cell volume by video microscopy suggest that Na+/K+/2C1 -cotransport contributes to both the maintenance of cell volume under isotonic conditions and the response to osmotic stress (Clemo and Baumgarten, 1991a; Drewnowska and Baumgarten, 1991) .
Rather than functioning at a static rate, Na+/K+/2CI-cotransport is modulated by several hormones including atrial natriuretic factor (ANF), a peptide produced by the heart that has vasodilatory, natriuretic, and diuretic properties. ANF stimulates Na+/K+/2CI -cotransport in rat aortic vascular smooth muscle (O'Donnell and Owen, 1986) , but inhibits the cotransporter in flounder intestinal epithelium (O'Grady, Field, Nash, and Rao, 1985) and cultured bovine aortic endothelial cells (O'Donnell, 1989) . Both the inhibition and stimulation of Na+/K+/2C1 -cotransport in these systems is attributed to an ANF-induced increase in the cytosolic level of guanosine 3',5'-monophosphate (cGMP). Na +/K +/2C1-cotransport is not regulated by cGMP in some other tissues, however. Instead, adenosine 3',5'-monophosphate (cAMP) stimulates cotransport in avian erythrocytes and epithelial cells (Palfrey and Rao, 1983) , but inhibits it in human erythrocytes (Garay and Ciccone, 1982) . Modulation of Na+/K+/2CI-cotransport by vasopressin and bradykinin has also been noted (Brock, Brugnara, Canessa, and Gimbrone, 1986) .
We recently provided evidence that ANF inhibits Na+/K+/2C1 -cotransport in both atrial and ventricular myocytes and thereby decreases cardiac cell volume (Clemo and Baumgarten, 1991a) . Although ANF acts by stimulating particulate guanylate cyclase and elevating the intracellular cGMP concentration in many systems Tremblay, Gerzer, and Hamet, 1988; Wildey, Misono, and Graham, 1992) , either cAMP or cGMP could be involved in the control of Na+/K+/2C1 -cotransport in heart. ANF stimulates particulate guanylate cyclase and increases cGMP in rabbit (Cramb, Banks, Rugg, and Aiton, 1987) and rat (Rugg, Aiton, and Cramb, 1989; McCall and Fried, 1990 ) myocytes as well as rabbit Purkinje fibers (Anand-Srivastava, Thibault, Sola, Fon, Ballak, Charbonneau, Haile-Meskel, Garcia, Genest, and Cantin, 1989) . On the other hand, ANF is reported to decrease cAMP in atrial and ventricular myocytes (Anand-Srivastava and Cantin, 1986) and Purkinje fibers (Anand-Srivastava et al., 1989) . Cramb et al. (1987) found that cAMP in ventricular myocytes was unaffected by ANF, however.
The present experiments suggest that ANF decreases ventricular cell volume by stimulating guanylate cyclase, increasing cytoplasmic cGMP, and thereby slowing Na+/K+/2C1 -cotransport. Moreover, changes in cell volume observed on inhibiting guanylate cyclase or cGMP-specific phosphodiesterase in the absence of ANF imply that basal cGMP levels are a determinant of cell volume under isotonic conditions. Some of these studies were reported previously in abstract form (Clemo and Baumgarten, 1991b) .
METHODS

Cell Isolation Procedure
Ventricular myocytes were isolated from adult rabbits (New Zealand White, 1.5-2.5 kg) with collagenase and pronase as previously described (Poole, Halestrap, Price, and Levi, 1989; Clemo and Baumgarten, 1991a) . For cell isolation, the Ca2+-free modified Tyrode's solution was supplemented with (mM): 20 taurine, 10 creatine, 0.4 NaH2PO4, and 3.5 MgClz instead of MgSO4 (pH 7.25, bubbled with 100% 02). Myocytes were temporarily stored in KB solution and were used within 6 h of harvesting. This procedure typically gave > 60% rod-shaped, Ca~+-tolerant, viable cells. Only nonbranching, quiescent cells without membrane blebs were chosen for volume studies.
Solutions and Drugs
Modified Tyrode's solution contained (raM): 130 NaCI, 5 KCI, 2.5 CaCIz, 10 glucose, 1.2 MgSO4, and 5 HEPES (pH 7.4, bubbled with 100% 02). N-Methyl-D-glucamine chloride (NMDG; Sigma Chemical Co., St. Louis, MO) was substituted for NaCl to make Na+-free media, and the corresponding salts of methanesulfonic acid (CH3SO3H; Aldrich Chemical Co., Milwaukee, WI) were substituted for NaCl, KC1, and CaCI2 to make Cl--free media. Cells also were studied after swelling in hypotonic (0.8T) solutions as done previously (Clemo and Baumgarten, 1991a) . NaCI was held constant at 65 mM, and the osmolarity was adjusted by adding mannitol to make either a hypotonic (0.8T; 60 raM) or isotonic (IT; 138 mM) medium. We have shown that partial substitution of mannitol for NaCI in isotonic solution does not affect cell length, width, or volume (Drewnowska and Baumgarten, 1991) . Measurements were made in flowing solutions (~ 5 ml/min), except when ANF was used. Because of ANF's expense, bath flow was stopped after 1 rain, a time sufficient to change bath volume > 10 times. In control studies, cells exposed to Tyrode's solution with flow stopped for 10 min showed no change in morphometric parameters. All experiments were done at room temperature (21-22°C), and a freezing point depression osmometer (Osmette S; Precision Systems Inc., Natick, MA) was used to verify bathing solution osmolarity.
[Serl°~-TyrlZ6]ANF (rat atriopeptin III; Calbiochem Corp., La Jolla, CA), 8-bromo-cGMP (8-Br-cGMP; Sigma Chemical Co.) and 8-Br-cAMP (Sigma Chemical Co.) were added to bathing media immediately before use. The rat and rabbit atrial peptides are identical (Wildey et al., 1992) . Stock solutions ofbumetanide (BUM; Hoffmann-La Roche, Nutley, N J), forskolin (Sigma Chemical Co.), Eli Lilly, Indianapolis, IN) , and 2-0-propoxyphenyl-8-azapurin-6-one (M&B22948, Zaprinast®; Rh6ne-Poulenc Rorer, Dagenham, Essex, UK) were made in dimethylsulfoxide (DMSO; Fluka Chemical Corp., Ronkonkoma, NY). DMSO did not affect cell volume at the final concentrations in the tissue bath (0.05-0.10%, vol/vol) (Drewnowska and Baumgarten, 1991; present results) .
Determination of Myocyte Dimensions
The determination of cell volume was previously described in detail (Clemo and Baumgarten, 199 l a) . In brief, a high-resolution TV camera was mounted on an inverted microscope (E. Leitz GmbH, Wetzlar, Germany) equipped with Hoffman modulation optics (Nikon × 40, 0.55 NA) and images were captured on-line by a video frame-grabber (Targa-M8; Truevision, Indianapolis, IN). The resolution of the digitization was ~ 0.25 Ixm/pixel. A commercial image analysis program (JAVA; Jandel Scientific, Corte Madera, CA) providing contrast enhancement and image magnification in software, and a custom program written in ASYST (Keithley Asyst, Rochester, NY) were used to determine the area of the cell's image, cell width at 1-~m intervals, and cell length.
Assuming that changes in cell width and thickness in test solutions are proportional, relative cell volume was determined as: volumet/volumec = (areat × widtht)/(areac x widthc) where t and c refer to test (e.g., ANF) and control solutions, respectively. We previously showed that changes in cell width and thickness are proportional with osmotic stress (Drewnowska and Baumgarten, 1991) . Based on repeated measurements of single images and measurements of multiple images of a cell, the estimates of cell volume (i.e., area x width) were reproducible to < 1% (Clemo and Baumgarten, 1991a; Drewnowska and Baumgarten, 1991) .
In the present studies, virtually all of the changes in relative cell volume resulted from changes in cell width (and thickness) rather than cell length. For an exemplar 25 p~m x 25 ~m × 150 ~m cell, a 10% decrease in relative cell volume at a constant length corresponds to a ~ 1.3-1~m decrease in cell width, and under optimal conditions, a 2-3% decrease in relative cell volume (i.e., ~ 0.3-0.4 I~m decrease in cell width) was shown to be statistically significant. This resolution depends in part on the fact that cell width represents an average calculated from ~ 150 measurements. For purposes of determining the lateral position of an image, the lowest resolution component of the system was the frame-grabber. According to Inou6 (1989) , microscope optics readily permit lateral position measurements to within < 10% of the Airy disk radius. For the present optics, the Airy disk radius was calculated as ~ 0.5 I~m.
Determination of cGMP
To verify the effects of ANF, LY83583, and M&B22948 under the present experimental conditions, cGMP levels in myocytes were determined by 125I-radioimmunoassay using a commercially available kit (NEN Research, E.I. Dupont de Nemours & Co., Boston, MA) adapted from the protocols of Steiner, Parker, and Kipnis (1972) . Myocytes were washed three times in ~40 times their volume of Tyrode's solution and allowed to settle by gravity. Aliquots (0.1 ml; 4.30-6.48 × 106 cells/ml) were resuspended in Tyrode's solution with or without drug to give a final volume of 0.5 ml. At selected times, the reaction was stopped with 0.5 ml of 10% trichtoroacetic acid, and the myocytes were homogenized for 15 s four times (model SDT1810, 10 mm shaft, maximum speed; Tekmar Co., Cincinnati, OH). After centrifugation (~ 1,200g, 10 min), 0.8 ml of the supernatant was extracted six times with 2-ml portions of water-saturated diethyl either to remove the trichloroacetic acid, and the aqueous phase was evaporated to dryness at 60°C under a stream of dry N~. The residue was dissolved in 0.8 or 1.0 ml of 50 mM sodium acetate buffer (pH 6.2), and 0.1-ml aliquots were acetylated and assayed for cGMP in duplicate according to kit instructions. The duplicate assays were averaged and corrected for cGMP recovery based on the recovery of 91 --+-2% (n = 3) of marker [3H]cGMP.
Statistics
Data are reported as mean -+ standard error; n represents the number of cells. After analysis of variance, multiple comparisons were made by the Bonferroni method. When only a single comparison was planned, Student's t test was used. The null hypothesis was rejected for P < 0.05.
RESULTS
Width, length, and volume of ventricular myocytes were initially measured in Tyrode's solution. The dimensions of ventricular cells were: width, 25.0 + 1.5 ~m; length, 147.5 -4.5 ~zm (n = 17). Calculation of cell volume as area × width, assuming cells are brick-shaped with equal width and thickness, gave a volume of 97.0 + 12.5 pl. If a cylindrical rather than a brick shape is assumed, cell volume was 76.2 + 9.8 pl (i.e., in a ratio of 4/rr). Uncertainty regarding absolute volume also arises because cell width and thickness may not be equal. For rabbit ventricular cells, however, the ratio of minor-to-major cross-sectional axis is ~ 0.8, and cells settle on either axis (Nassar, Reedy, and Anderson, 1987; Drewnowska and Baumgarten, 1991) . To avoid these uncertainties, each cell was used as its own control and subsequent experimental values are presented relative to control values. The small decrease between 5 and 20 min was not significant. Cell volume returned to its initial value after 10 min of washout of 8-BrcGMP. ANF (B) and SNP (C) decreased cell volume to 0.918 +--0.006 (n = 5) and 0.889 -+ 0.009 (n = 5), respectively, within 2 rain, and volume remained stable thereafter. In both cases, cell volume returned to its initial value after 5 min of washout.
8-Br-cGMP Reduces Ventricular Cell Volume
If cGMP is a second messenger for ANF in heart, 8-Br-cGMP, a nonmetabolizable, membrane-permeant analogue of cGMP, should mimic the effect of ANF on cell volume. Fig. 1 A shows that exposure to 10 IxM 8-Br-cGMP for 20 min decreased the volume of ventricular myocytes. Cell volume was significantly less than control after 2 rain in 8-Br-cGMP-containing Tyrode's solution, and decreased to 0.904 + 0.005 (n = 5) after 5 rain. Thereafter, cell volume did not significantly change, although the minimum volume, 0.892 +--0.007, was attained at 20 min. Cell shrinkage occurred because of a decrease in cell width; 8-Br-cGMP did not significantly affect cell length. Upon washout of 8-Br-cGMP, cell volume returned to its initial value within 10 min. For comparison, the time course of cell volume reduction caused by 1 ~M ANF, a maximally effective concentration (Clemo and Baumgarten, 1991a) , is illustrated in Fig. 1 B. The ANF-induced shrinkage and washout were more rapid than those for 8-Br-cGMP. The decrease in cell volume with ANF, 0.918 + 0.006 (n = 5), was complete at 2 rain, and control volume was restored by 5 min of washout. As with 8-Br-cGMP, the decrease in volume occurred without a significant change in cell length. The slower onset and washout of 8-Br-cGMP were probably due to the time required for it to cross the cell membrane. Nevertheless, the effect of 10 ~M 8-Br-cGMP on cell volume was slightly greater than the maximum effect of ANF.
An important class of agents that increase cGMP levels in heart is the nitrovasodilators, such as sodium nitroprusside (Diamond, Ten Eick, and Trapani, 1977) (Murad, Mittal, Arnold, Katsuki, and Kimura, 1978) . As shown in Fig. 1 C, exposure to 100 ~M sodium nitroprusside (SNP) also rapidly and reversibly decreased cell volume. After 20 rain in SNP, cell volume was 0.889 -+ 0.009 (n = 5) relative to that in control. As in the previous protocols, the decrease in cell volume occurred without a significant change in cell length. The decrease in cell volume achieved by elevating cGMP with SNP was indistinguishable from that observed with 8-Br-cGMP. Thus, effects on cardiac cell volume were not peculiar to 8-Br-cGMP. Volume reduction on application of 8-Br-cGMP was dose dependent, and a cumulative dose-response curve is depicted in Fig. 2 . Relative volume was significantly less than control after 5-min exposures to 0.01, 0.1, 1, 10, and 100 ~M 8-Br-cGMP, but the shrinkages induced by 10 and 100 ~M 8-Br-cGMP were not significantly different. A dose-response curve was constructed for each cell assuming a single occupancy binding model. Based on this analysis, the EDs0 was 0.77 +-0.33 ~M (n = 7). Because there are probably several steps between the binding of 8-Br-cGMP and reduction of' cell volume, the EDs0 is likely to differ from the Kd for cyclic nucleotide binding.
Whereas 8-Br-cGMP significantly reduced cell volume, cell volume was unaffected by 0.01-100 ~M 8-Br-cAMP (Fig. 2) . For example, the volume of ventricular cells after a 5-min exposure to 100 p,M 8-Br-cAMP was 1.006 -+-0.008 (n = 10), a value not different from control. Lengthening 8-Br-cAMP exposure to 10 rain was also ineffective. Finally, a 10-rain exposure to 50 ~M forskolin, an activator of adenylate cyclase, did not alter cell volume (n = 5; see also Fig. 7 ).
Although the simplest explanation for the data in Figs. 1 and 2 is that cell volume is modulated by cGMP and not by cAMP, an alternative mechanism should be considered. A cGMP-dependent phosphodiesterase that is stimulated by cGMP and catalyzes the hydrolysis of cAMP has been reported (Beavo, 1988; Weishaar, Kobylarz-Singer, Keiser, Haleen, Major, Rapundalo, Peterson, and Panek, 1990) . Furthermore, cAMP levels in heart tissues of some species are decreased by ANF while cGMP is elevated (Anand-Srivastava and Cantin, 1986; Anand-Srivastava et al., 1989 ). It is possible, then, that 8-Br-cGMP decreases cAMP levels by increasing its rate of degradation, and that a decline of cAMP levels, rather than elevation of cGMP, is the proximate cause of the fall in cell volume.
To test the idea that a decrease in cAMP leads to reduction of cell volume, cells were pretreated with 100 ~M 8-Br-cAMP to "clamp" the cAMP level and then exposed to 8-Br-cGMP. Cell volume did not change during the 5-min pretreatment with 100 I~M 8-Br-cAMP. Upon addition of 10 ~M 8-Br-cGMP, however, volume decreased to 0.910 +-0.008 (n = 5) in 10 min. This decrease in volume was indistinguishable from that observed without 8-Br-cAMP in the bath, and the results suggested that a fall in cAMP is not required for 8-Br-cGMP to elicit cell shrinkage.
cGMP Blocks Na+ /K+ /2Cl -Cotransport
We previously reported that inhibiting Na+/K+/2C1 -cotransport decreases cardiac cell volume (Clemo and Baumgarten, 1991a; Drewnowska and Baumgarten, 1991) . Fig. 3 tests the hypothesis that 8-Br-cGMP reduces cardiac cell volume by blocking the same cotransporter. If the hypothesis is correct, inhibiting Na+/K+/2CI -cotransport with BUM should preclude the action of 8-Br-cGMP. Fig. 3 A depicts the effect of pretreating with 10 ~M BUM in isotonic Tyrode's solution. BUM decreased myocyte volume to 0.887 + 0.009 (n = 5), and exposure to 10 ~M 8-Br-cGMP failed to induce further shrinkage of BUM-treated cells (squares). Volume returned to its control value after 20 min of washout of BUM and 8-Br-cGMP. The crucial issue, the effect of 8-Br-cGMP on BUM-treated cells, is more clearly addressed by calculating cell volume relative to that in BUM (circles). Expressed in this way, cell volume in BUM plus 8-Br-cGMP was 0.996 -+ 0.009, a value indistinguishable from unity.
Although Fig. 3A is consistent with the idea that cGMP inhibits Na+/K+/2CI-cotransport, it might be argued that physical shrinkage caused by BUM, rather than its inhibition of the cotransporter, attenuated the effect of 8-Br-cGMP on cell volume. To rule out this possibility, the effect of BUM pretreatment on the response to 8-Br-cGMP was evaluated in osmotically swollen cells (Fig. 3 B) . Previously we showed that the volume of rabbit myocytes remains stable in hypotonic solutions rather than THE JOURNAL OF GENERAL PHYSIOLOGY " VOLUME 100 " 1992 undergoing a regulatory volume decrease (Drewnowska and Baumgarten, 1991) . To eliminate the chance that BUM-induced shrinkage prevented ANF's effect, the study was repeated in cells preswollen in 0.8T media for 10 min. Although cell volume after a 10-min exposure to BUM in 0.8T solution remained greater than the volume in 1T solution (squares), 8-Br-cGMP still did not significantly alter volume after 10 min. Cell volume in BUM plus 8-Br-cGMP was 0.998 -0.008 relative to that in BUM alone (circles). n = 6 cells. In both panels volume returned to its initial value after 20 min of washout in IT. 0.998 + 0.008 after the challenge with 8-Br-cGMP (circles). These results argue that cell shrinkage itself cannot account for the suppression of the effect of 8-Br-cGMP by BUM.
Na+/K+/2CI-cotransport requires extracellular Na + and CI-, and removal of these ions from the bathing solution blocks the cotransport process (Geck, Pietrzyk, Burckhardt, Pfeiffer, and Heinz, 1980; O'Grady et al., 1987) . If 8-Br-cGMP shrinks cells by blocking Na+/K+/2CI -cotransport, it should have no effect on cells that are bathed in either Na +-or C1--free media since Na+/K+/2CI-cotransport would have already been inhibited. This prediction is tested in Fig. 4 . Cell volume decreased to 0.952 + 0.005 (n = 5) after 10 min in Cl--free 1T media (Fig. 4A ). Exposure to 10 IxM 8-Br-cGMP did not decrease cell volume further. Cell volume was 0.947 +__ 0.007 of the control volume (squares) or 0.995 + 0.006 of that in C1--free medium alone (circles). To ensure that shrinkage caused by Cl--free medium was not responsible for blocking cGMP's effect, this experiment was repeated in five osmotically swollen cells, as shown in Fig. 4 B. When the bathing solution was changed from Cl--free 1T to Cl--free 0.8T solution, relative cell volume increased over 10 min from 0.943 + 0.006 to 1.092 + 0.006. 8-Br-cGMP did not significantly change cell volume under these conditions either. Relative to cell volume in 0.8T Cl--free media, cell volume was 1.003 + 0.005 after exposure to 10 p.m 8-Br-cGMP (circles).
The Na ÷ dependence of cGMP's effect is demonstrated in Fig. 4 C. Removal of Na + for 10 min decreased cell volume to 0.950 + 0.010 (n = 4). In the absence of Na +, 10 IxM 8-Br-cGMP did not significantly alter cell volume. Relative to cell volume in Na+-free solution, cell volume was 1.007 + 0.014 after exposure to 8-Br-cGMP (circles). To check whether the shrinkage caused by Na+-free solution interfered with the action of cGMP, this experiment was repeated in five osmotically swollen cells (Fig. 4 D) . Exposure to Na+-free 0.8T solution increased volume from 0.954 +-0.007 to 1.086 _+ 0.009. Again, 10 p.M 8-Br-cGMP did not significantly change cell volume. After treating cells with 8-Br-cGMP, cell volume was 1.001 -+ 0.014 of that in Na+-free 0.8T solution (circles). These experiments establish that the effect of 8-Br-cGMP depends on two of the ions required for Na+/K+/2C1-cotransport, extraceUular Na + and CI-.
Is cGMP the Second Messenger for ANF-induced Cardiac Cell Shrinkage?
The experiments presented so far show that 8-Br-cGMP and elevating cGMP with SNP mimic the effect of ANF on cell volume (Fig. 1) and suggest that cGMP, like ANF (Clemo and Baumgarten, 1991a) , reduces cell volume by inhibiting Na+/K+/ 2C1-cotransport. Because ANF increases cytosolic cGMP levels in heart by stimulating guanylate cyclase (Cramb et al., 1987; Anand-Srivastava et al., 1989; Rugg et al., 1989) and ANF modulates Na+/K+/2CI-cotransport in other tissues via cGMP (O'Grady et al., 1985; O'Donnell and Owen, 1986; O'Donnell, 1989) , it is appealing to postulate that cGMP is the second messenger for ANF-induced cardiac cell shrinkage.
One test of the idea that cGMP is the second messenger of ANF-induced cardiac cell shrinkage is shown in Fig. 5 . As expected for a second messenger system, pretreating cells with 8-Br-cGMP, an analogue of the putative second messenger, attenuated the effect of ANF. Exposure to 10 IxM 8-Br-cGMP shrank cells in isotonic Tyrode's solution to 0.887 + 0.012 (n = 5) of their control volume, and the addition of 1 ~M ANF did not further affect cell volume ( Fig. 5A; squares) . Relative to cell volume in 8-Br-cGMP-containing media, cell volume after addition of ANF was 1.006 + 0.009 (circles). As before, this experiment was repeated in osmotically swollen cells to demonstrate that shrinkage caused by 8-Br-cGMP did not interfere with ANF's action (Fig. 5 B) . In cells swollen by exposure to 0.8T solution, 10 IzM 8-Br-cGMP reduced cell volume from 1.177 + 0.013 to 1.046 + 0.008 (n = 7). After Relative to volume in C1--or Na÷-free medium alone, volume after a 10-rain exposure to 10 I.tM 8-Br-cGMP was 0.995 +-0.006 and 1.007 _+ 0.014, respectively (circles). Shrinkage in C1--or Na+-free medium was not responsible for lack of effect of 8-Br-cGMP (B and D). Cells were exposed to CI--or Na+-free 1T medium for 10 min, and then were swollen in Ci--free or Na+-free 0.8T medium for 10 min. Cell volume remained greater than control in 0.8T Cl--free and 0.8T Na +-free solutions, 1.092 + 0.006 (n = 5) and t.086 -+ 0.009 (n = 5), respectively (squares), but 8-Br-cGMP still failed to reduce cell volume. Relative to cell volume in CI--and Na +-free 0.8T media, volume was 1.003 + 0.005 and 1.001 -+ 0.014, respectively, after a 10-min exposure to 10 I~M 8-BrcGMP (circles). In each case, initial volume was restored after 20 rain of washout.
addition of 1 IxM ANF, cell volume was 1.044 ± 0.004 relative to the control volume or 0.998 ± 0.007 relative to the volume in 8-Br-cGMP 0.8T solution (circles). This small change in cell volume was not significant.
If ANF causes cell shrinkage by increasing intracellular cGMP levels, pretreatment of cells with ANF should attenuate the effect of exogenously applied 8-Br-cGMPjust as pretreatment with 8-Br-cGMP blocked the action of ANF. To demonstrate this, the experiments depicted in Fig. 5 were repeated with the order of application of ANF and 8-Br-cGMP reversed. Cells were first swollen in 0.8T solution for 10 rain, and then exposed for 10 rain to 8-BrcGMP in 0.8T solution. Volume in 0.8T solution with 8-BrcGMP was 1.046 +-0.008 (squares), a value slightly greater than control. ANF was not effective under these conditions either. Relative to cell volume in 0.8T solution with 8-BrcGMP, volume after a 10-min exposure to ANF was 0.998 ---0.007 (n = 7; circles). In both cases, initial volume was restored after 20 min of washout.
of 10 IxM 8-Br-cGMP caused a further significant reduction of cell volume to 0.896 ± 0.007 or 0.969 ± 0.007 of the volume of ANF-treated cells (circles). Although the 3.1% decrease in cell volume caused by 8-Br-cGMP after pretreatment with ANF was significant, it was significantly smaller than the 10.8% decrease caused by 8-Br-cGMP alone (see Fig. 1 ). That is to say, ANF markedly attenuated the effect of 8-Br-cGMP but did not block it completely. Similar results were obtained when this protocol was repeated in osmotically swollen cells, as is illustrated in Fig. 6 B. Treatment with 1 I~M ANF reduced cell volume from 1.181 +_ 0.005 to 1.105 +-0.009, and addition of 10 t~M 8-Br-cGMP reduced volume further to 1.057 ± 0.007 (n = 5). Relative to the volume in 0.8T media containing ANF, cell volume after exposure to 8-Br-cGMP was 0.957 -+ 0.010. Again, this 4.3% reduction of cell volume is much less than that caused by 8-Br-cGMP alone.
As discussed above, 8-Br-CAMP did not effect cell volume and 8-Br-cGMP did not shrink cells by decreasing intracellular cAMP. Fig. 7 illustrates two sets of experiments that rule out the possibility that a component of ANF's effect on cardiac cell volume is mediated by a reduction of CAMP levels. Two methods were used to activate the CAMP system. In both cases, initial volume was restored after 20 rain of washout.
8-Br-cAMP, and Fig. 7 B shows pretreatment with 50 IzM forskolin, an activator of adenylate cyclase. As expected from the data illustrated in Fig. 2 , neither agent significantly altered cell volume. A more important result is the response to ANF while the cAMP system was activated. After pretreatment with 8-Br-cAMP, 1 ~M ANF reduced cell volume from 0.995 + 0.007 to 0.923 -+ 0.007 (n = 5), and after forskolin, from 1.004 + 0.008 to 0.925 -+ 0.008 (n = 5). The ~ 8% decreases in cell volume induced by 1 p~M ANF in these pretreatment protocols were indistinguishable from that observed with 1 I~M ANF alone, 8.2% ( Fig. 1 ; also see Clemo and Baumgarten, 1991a) . The results argue that ANF does not cause cell shrinkage by virtue of decreasing cytoplasmic cAMP levels. Another prediction of the hypothesis that cGMP mediates the cell volume effect of ANF can be tested. If cGMP is the second messenger for ANF, the effect of ANF should be attenuated by manipulations that decrease cGMP production and should be amplified by manipulations that decrease cGMP breakdown. Fig. 8 illustrates the effect of LY83583, which inhibits guanylate cyclase in heart (Schmidt, Sawyer, Truex, Marshall, and Fleisch, 1985; MacLeod and Diamond, 1986) and should suppress an ANF-induced increase in cGMP. First, the responsiveness of cells to ANF was verified; in these six cells, 1 ~M ANF decreased cell volume by 8% to 0.920 -+ 0.004. Then, The shrinkage observed under these conditions is not significantly different from that observed with ANF alone, 0.918 _+ 0.006 (see Fig. 1 ). In both cases, initial volume was restored after 20 rain of washout.
after washout of ANF, cells were exposed to 10 ~M EY83583. LY83583 caused a small but significant increase in cell volume from 0.999 -+ 0.004 to 1.019 -+ 0.005 (squares) after 10 min, and similar data were obtained after only 5 rain. Finally, ANF was added to the bath. Cell volume significantly decreased when LY83583-treated cells were exposed to 1 ~M ANF, but the change in volume was much smaller than with ANF alone. Relative to volume in LY83583, 1 ~M ANF decreased volume to 0.980 -+ 0.004 (circles) in treated cells, a 2% change. Attenuation of the effect of ANF on cell volume by LY83583 is consistent with the idea that cGMP is the second messenger for ANF. decrease in cell volume was significantly less than the 8% decrease in cell volume to caused by 1 ~.M ANF alone. Initial volume was restored after 20 min of washout of both ANF and LY83583. n = 6 cells.
According to our working hypothesis, slowing degradation of cGMP should potentiate the effect of a submaximal dose of ANF. To test this idea, we used M&B22948, a cGMP-specific phosphodiesterase (class Ic) inhibitor (Lugnier, Stierle, Beretz, Schoeffter, Lebec, Wermuth, Cazenave, and Stoclet, 1983; Brunkhorst, v der Leyden, Meyer, Nigbur, Schmidt-Schumacher, and Scholz, 1989; Weishaar et al., 1990) . Fig. 9 shows the response to 0.01 ~M ANF, a dose near threshold for detecting a volume change; the ED50 for ANF-induced volume reduction is 0.072 I~M (Clemo and Baumgarten, 1991a) . This dose of ANF, which was 100-fold lower than that used in the preceding experiments, caused a small decrease of cell volume to 0.977 + 0.004 (n = 6). After washout of ANF, cells were treated with 100 o,M M&B22948, which reduced cell volume from 1.005 -+ 0.006 to 0.967 -0.004 Fig. 10 depicts experiments designed to test whether the effects of LY83583 and M&B22948 on cell volume involve cGMP and Na+/K+/2CI -cotransport. Although LY83583 and M&B22948 are inhibitors of cardiac guanylate cyclase (Schmidt et al., 1985; MacLeod and Diamond, 1986) and cardiac cGMP-specific phosphodiesterase (Brunkhorst et al., 1989) , and we have suggested that cGMP modulates cell volume via Na+/K+/2CI -cotransport, it is possible that these agents affect cardiac cell volume by multiple means. Fig. 10A illustrates the interactions between LY83583 and both 8-Br-cGMP and BUM. By itself, 10 p~M LY83583 caused a small but significant increase of cell volume to 1.021 -+ 0.008 (n = 4). LY83583 was ineffective after Na+/K+/2CI-cotransport was inhibited by 10 p,M 8-Br-cGMP or 10 p,M BUM, however (circles). This is consistent with the idea that LY83583 acts solely by augmenting the production of cGMP and thereby decreasing ion accumulation by Na+/K+/2CI-cotransport. 8-Br-cGMP and BUM should inhibit cotransport, preventing the effect of LY83583. Fig. 10 B depicts similar experiments with M&B22948. Treatment with 10 t~M M&B22948 induced a small but significant decrease of cell volume to 0.968 + 0.006 (n = 4). As expected for an agent acting solely by inhibiting cGMP-specific phosphodiesterase, M&B22948 did not alter cell volume after exposure to 10 ~M 8-Br-cGMP or 10 p,M BUM (circles). Inhibition of cotransport by 8-Br-cGMP or BUM should avert the effect of the accumulation of cGMP on cell volume. Fig. 10 C verifies the mechanism of action of M&B22948 in another way. Block of guanylate cyclase by LY83583 is expected to abolish production of cGMP. Consequently, inhibition of the cGMP-specific phosphodiesterase should alter neither the cytoplasmic cGMP level nor cell volume. This expectation was confirmed. Relative to cell volume in 10 p.M LY83583, cell volume after exposure to 10 p~M M&B22948 was 0.992 + 0.006 (n = 5; circles), a value indistinguishable from unity.
The Mechanism of Action of LY83583 and M&B22948
Effects of ANF, LY83583, and M&B22948 on cGMP Levels in Myocytes
Interpretation of the results presented up to this point depends in part on previous descriptions of the effects of ANF (Cramb et al., 1987; Anand-Srivastava et al., 1989; Rugg et al., 1989; McCall and Fried, 1990) , LY83583 (Schmidt et al., 1985; MacLeod and Diamond, 1986) , and M&B22948 (Lugnier et al., 1983; Brunkhorst et al., 1989; Weishaar et al., 1990 ) on cGMP levels in heart. Therefore, 125I-cGMP radioimmunoassay was used to confirm that the key elements of previous findings were applicable to isolated ventricular myocytes under the present experimental conditions. Fig. 11 A demonstrates that 1 pLM ANF rapidly increased cGMP levels in isolated myocytes and that elevated cGMP levels were well maintained throughout a 20-min exposure to ANF. cGMP was 0.25 + 0.01 pmol/106 cells in control myocytes, increased to 0.60 -+ 0.01 pmol/106 cells at 2 min, and reached 0.74 + 0.04 pmol/106 cells after 10 rain in 1 ~M ANF, a threefold increase. Thus, the time course of the rise of cGMP was consistent with that of the fall of cell volume (see Fig. 1 B) .
The interactions of ANF and both LY83583 and M&B22948 were examined in another set of experiments, illustrated in Fig. 11 B, which exactly paralleled the volume measurement studies (see Figs. 8 and 9 ). As expected from Fig. 11 A, exposure to 1 p,M ANF for 10 min increased cGMP to 0.72 ---0.02 pmol/106 cells, nearly threefold greater than in control cells. The guanylate cyclase inhibitor LY83583 significantly decreased, but did not totally eliminate, the response to 1 CM ANF. After 10 min in 10 ~M LY83583, exposure to 1 p,M ANF for 10 min in the continued presence of LY83583 increased cGMP to 0.42 + 0.02 pmol/106 cells, an increase of only ~50% rather than threefold. By itself, however, LY83583 did not significantly alter cGMP levels.
The response to the cGMP-specific phosphodiesterase inhibitor M&B22948 also was as expected (Fig. 11 B) . First, a 10-min exposure to 100 ~M M&B22498 more than doubled the cGMP level. Second, M&B22948 markedly potentiated the ability of a low dose of ANF to elevate cGMP. By itself, treatment with 0.01 tzM ANF for 10 min caused a small but significant increase in cGMP from 0.28 -0.02 (10 min control) to 0.35 -0.01 pmol/106 cells. After 10 min of pretreatment with M&B22948, however, exposure to 0.01 IxM ANF in the continued presence of M&B22948 elevated cGMP to 1.36 -0.56 pmol/106 cells, a fourfold higher level. FIGURE 11. ~eSI-cGMP radioimmunoassay determinations of cGMP levels in isolated cardiac myocytes. Separate aliquots of cells were used for each time point or condition, and each cGMP assay was done in duplicate, averaged, and corrected for recovery. (A) Exposure to 1 I~M ANF for 20 rain induced a rapid and sustained elevation of cGMP. cGMP was already significantly greater than in control cells after a 2-min exposure to ANF, and was 0.64 + 0.02 pmol/106 cells, 2.6 times higher than control, after 20 min. n = 3 or 2 per time point.
(B) Inhibition of guanylate cydase by 10 I~M LY83583 (LY) significantly decreased ANF-induced accumulation of cGMP, and inhibition of cGMP-specific phosphodiesterase by I00 ~M M&B22948 (MB) significantly increased ANF-induced accumulation of cGMP. Bars represent (left to right) 10-and 20-min untreated controls and the effects of 1 ~M ANF for 10 min, LY for 10 rain, LY for 10 rain followed by exposure to both 1 I~M ANF and LY for 10 min, 0.01 txM ANF for 10 min, MB for 10 min, and MB for 10 rain followed by exposure to both 0.01 ~M ANF and MB for 10 rain. n = 5 or 4 per condition.
These studies confirm that under present conditions LY83583 and M&B22948 have the expected effects on ANF-induced cGMP accumulation.
DISCUSSION
These experiments demonstrate for the first time that cGMP and 8-Br-cGMP, its membrane permeant analogue, modulate ventricular cell volume. Furthermore, they suggest that cGMP is the second messenger in the reduction of cell volume by ANF.
Previously it was shown that ANF activates guanylate cyclase in heart and increases the cytoplasmic concentration of cGMP (Cramb et al., 1987; Anand-Srivastava et al., 1989; Rugg et al., 1989; McCall and Fried, 1990) , a finding confirmed in the present study. We propose that the increase in cGMP causes shrinkage of myocytes by inhibiting Na+/K+/2C1-cotransport. The results are summarized diagrammatically in Fig. 12. FIGURE 12. Schematic model of the mechanism of action of ANF and cGMP on cell volume. Binding of ANF to a sarcolemmal receptor activates (+) a particulate guanylate cyclase, which may be a portion of the receptor molecule (Wildey et al., 1992) , leading to the conversion of guanosine triphosphate (GTP) to 3',5'-cGMP. SNP activates a soluble guanylate cyclase and also elevates cGMP (Diamond et al., 1977; Murad et al., 1978) . By one or more steps, cGMP inhibits (-) Na+/K+/2CI-cotransport. LY83583 inhibits guanylate cyclase, resulting in reduced accumulation of cGMP upon stimulation with ANF, and M&B22948 inhibits cGMP-specific phosphodiesterase, resulting in enhanced accumulation of cGMP upon stimulation with ANF. Other phosphodiesterases (not shown) may also contribute to the degradation of cGMP to 5'-GMP. Adenosine triphosphate (ATP) is required at a regulatory site. In the steady state, the influx of osmolytes via Na + /K ÷/2C1-cotransport and obligate influx of water must be balanced exactly by efflux processes (not shown). Therefore, inhibition of Na+/K+/2CI -cotransport results in the net efflux of osmolytes and water, and cell shrinkage ensues.
Does cGMP Reduce Cell Volume by Inhibiting Na+/K+/2Cl -Cotransport?
Cell shrinkage represents the net loss of osmolytes and cell water. Either a stimulation of the effiux or an inhibition of the influx of osmotic equivalents by cGMP or 8-Br-cGMP could explain the shrinkage of ventricular myocytes. The most likely possibility is that cGMP and 8-Br-cGMP inhibit ion uptake by Na+/K+/2CI -cotransport. This conclusion is based on the finding that BUM, a blocker of Na+/K+/2C1-cotransport (Schlatter, Greger, and Weidtke, 1983; Clemo and Baumgarten, 1991a) , prevented volume reduction by 8-Br-cGMP. Once Na+/K+/2C1-cotransport is fully inhibited by BUM, agents that act solely by inhibiting the same transporter should be ineffective. The EDs0 for reduction of cell volume by 8-Br-cGMP, ~0.8 ~M, is comparable to the 8-Br-cGMP sensitivity of Na+/K+/2C1-cotransport in other tissues (O'Donnell and Owen, 1986; O'Donnell, 1989) .
Additional evidence that 8-Br-cGMP brings about cell shrinkage by inhibiting Na+/K+/2CI-cotransport is that removal of either Na + or CI-from the bathing media blocked its action. The ionic requirements for cell shrinkage by 8-Br-cGMP match those for Na+/K+/2CI -cotransport (Geck et al., 1980; O'Grady et al., 1987) . Replacing Na + or C1-with ions that are not transported should preclude further inhibition of transport by 8-Br-cGMP. The dependence of 8-Br-cGMP's effect on extracellular K + was not tested because complete removal of extracellular K + results in spontaneous activity of myocytes.
Shrinkage on removal of Na + or CI-was less than that observed with 8-Br-cGMP, however. Shrinkage was not limited by the leak of Na + and CI-substitutes into the cell. If they did leak in, volume should overshoot on returning to Na + or C1--containing solutions, but no overshoot was detected. The same apparent discrepancy was noted previously with BUM and ANF. By themselves, these agents decrease cell volume by ~ 12 and ~ 8%, but like 8-Br-cGMP, their actions are totally blocked by removing Na + or C1-with only a ~ 4% decrease in volume (Clemo and Baumgarten, 1991a) . It may be inferred that besides a common effect to block Na+/K+/2CI-cotransport, either BUM, ANF, and 8-Br-cGMP or Na + and CI-removal must have additional effects on ion transport. There is an intrinsic difference in stopping Na+/K+/2CI-cotransport in these two ways. On removal of Na + or CI-, intracellular cation or anion cannot be lost alone because of the requirement for macroscopic electroneutrality. If loss of Na + is partially compensated for by gain of K ÷ or loss of CI-by gain of HCO~, the decrease in volume would be less than expected, as has been shown to be the case (Clemo and Baumgarten, 1991a) . In contrast, inhibiting Na+/K+/2C1-cotransport directly does not disturb macroscopic electroneutrality and causes the net loss of these ions with a fixed stoichiometry. Taken together, these data suggest but do not prove that the differences in shrinkage may be a consequence of how macroscopic electroneutrality is maintained in each case.
An alternative idea is that 8-Br-cGMP produced cell shrinkage by stimulating an efflux of osmolytes. In some tissues, passive K + and CI-efttux by separate conductive pathways coupled by macroscopic electroneutrality causes a volume regulatory decrease after osmotic swelling (Hoffman and Simonsen, 1989) . cGMP activates a poorly selective cation channel in retinal outer rod segments (Fesenko, Kolesnikov, and Lyubarsky, 1985; Yau and Nakatani, 1985; Furman and Tanaka, 1990) , olfactory receptor cilia (Nakamura and Gold, 1987) , A6 renal epithelial cells (Marunaka, Ohara, Matsumoto, and Eaton, 1991) , and a CI-channel in the T84 colonic cells (Lin, Nairn, and Guggino, 1991) . Although BUM appears specific for Na+/K+/2CI-cotransport in heart, it has been reported to block certain CI-channels in epithelia and nerve (Gallagher, Nakamura, and Shinnick-Gallagher, 1983; Landry, Reitman, Cragoe, and AI Awqati, 1987; Wang and Cooke, 1990) . Thus, one might argue that 8-Br-cGMP stimulates ion efflux and cell shrinkage by opening a BUM-sensitive CIchannel or a K + channel that is linked to a BUM-sensitive C1-channel by macroscopic electroneutrality. The results of several experiments run counter to this hypothesis, however. First, if BUM blocked CI-and K + efflux, it should increase cell volume. As shown here and previously (Clemo and Baumgarten, 1991a; Drewnowska and Baumgarten, 1991) , BUM significantly decreased cell volume. Second, BUM decreases intracellular CI-activity (Baumgarten and Duncan, 1987; Liu et al., 1987) . This is contrary to expectations for CI-channel block because the electrochemical gradient for C1-is outward in rabbit myocytes (D6silets and Baumgarten, 1986) . Third, BUM-induced cell shrinkage is inhibited by removing Na ÷ from the bathing solution (Clemo and Baumgarten, 1991a) . The conductive effiux of K ÷ and C1-should not require extracellular Na ÷.
Although the primary effect of cGMP appears to be Na+/K+/2CI-cotransport inhibition, the resultant modification of ionic gradients (Frelin et al., 1986; Baumgarten and Duncan, 1987; Liu et al., 1987) may affect other transport processes. For example, inhibition of Na+/K+/2C1-cotransport decreases intracellular Na ÷ activity (Liu et al., 1987) and therefore affects the Na+-K ÷ pump, Na+-Ca 2÷ exchange, and Na+-H + exchange. These processes may contribute to regulation of the cell volume directly by performing osmotic work or indirectly by altering intracellular Ca 2÷ and pH. Furthermore, we cannot exclude other direct effects of cGMP on transport processes.
Does 8-Br-cGMP Modulate Cell Volume by Altering cAMP Levels?
Although 8-Br-cGMP is often used to specifically activate cGMP-dependent processes, other pathways may be affected also. For example, 8-Br-cGMP stimulates a cAMP-specific phosphodiesterase (Beavo, 1988; Weishaar et al., 1990) , and myocyte shrinkage might ultimately depend on cAMP rather than cGMP-dependent mechanisms. Increasing cAMP stimulates Na+/K+/2C1-cotransport in avian erythrocytes and epithelial cells (Palfrey and Rao, 1983) but inhibits the cotransporter in bovine aortic endothelial cells (O'Donnell, 1989) , human erythrocytes (Garay and Ciccone, 1982) , and vascular smooth muscle (Owen, 1984) . In myocytes, however, cell volume was unaffected by up to 100 ~M 8-Br-cAMP and by activation of adenyl cyclase with 50 IxM forskolin. Furthermore, the possibility that 8-Br-cGMP acts by decreasing cAMP levels was also excluded. Because Na+/K+/2CI -cotransport is decisive in setting cardiac cell volume (Clemo and Baumgarten, 1991a; Drewnowska and Baumgarten, 1991) , one can conclude that cardiac Na+/K+/2CI-cotransport is not modulated by cAMP.
Is cGMP the Second Messenger for ANF-induced Myocyte Shrinkage?
It is well established that ANF receptors are linked to and activate guanylate cyclase and elevate cGMP in a number of tissues Tremblay et al., 1988; Wildey et al., 1992) including the heart (Cramb et al., 1987; AnandSrivastava et al., 1989; Rugg et al., 1989; McCall and Fried, 1990) . The increase in cGMP levels is transient in a few cell lines, but is maintained in many others including bovine aortic smooth muscle, canine kidney epithelial (MDCK), rat mammary epithelial, human lung fibroblast, bovine adrenal cortical, rat glioma, and rat pheochromocytoma cells (Fiscus, Roles, Waldman, and Murad, 1987; Leitman, Andresen, Catalano, Waldman, Tuan, and Murad, 1988) . In the present study, the ANF-induced increase in cGMP was well maintained in isolated ventricular myocytes for 20 min. This is consistent with the observation that cGMP in ventricular muscle is elevated after a 30-min exposure to ANF (McCall and Fried, 1990) . In contrast, in the presence of the phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine (IBMX, 1 raM) and reduced extracellular Ca 2+ (0.5 mM), ventricular cGMP levels are reported to begin to decrease after exposure to ANF for ~ 10 rain but remain significantly greater than control at 20 min (Cramb et al., 1987) . cGMP appears to be the second messenger for ANF in the sequence of steps leading to a reduction of myocyte cell volume. First, ANF rapidly increased cGMP levels in isolated myocytes. Second, 8-Br-cGMP and elevation of cGMP by SNP mimicked ANF in decreasing cell volume. Third, inhibition of guanylate cyclase and the production of cGMP with the quinolinedione LY83583 (Schmidt et al., 1985; MacLeod and Diamond, 1986) blunted both the ANF-induced elevation of cGMP and ANF-induced reduction of cell volume. LY83583 also attenuates ANF's inhibition of ion fluxes mediated by Na+/K+/2CI-cotransport in vascular endothelial cells (O'Donnell, 1989) . Fourth, inhibition of cGMP-specific phosphodiesterase and the degradation ofcGMP with M&B22948 (Lugnier et al., 1983; Brunkhorst et al., 1989; Weishaar et al., 1990) potentiated the effect of a threshold dose of ANF (0.01 p.M) so that myocyte shrinkage was comparable to that induced by a maximally effective dose. Correspondingly, after M&B22948 treatment, a threshold dose of ANF gave rise to a maximally effective increase in cGMP. M&B22948 also potentiates ANF's vasodilatory and natriuretic effects in rats and rabbits (Weishaar et al., 1990) and its stimulation of Na+/K+/2CI-cotransport in vascular smooth muscle (O'Donnell and Owen, 1986) . Fifth, pretreatment with a maximally effective dose of 8-Br-cGMP eliminated the ability of ANF to decrease cell volume. Such inhibition is required if ANF acts by elevating cGMP levels. Sixth, in the converse experiment, a maximally effective dose of ANF (Clemo and Baumgarten, 1991a ) markedly diminished cell shrinkage on exposure to 8-Br-cGMP. ANF did not totally prevent 8-Br-cGMPinduced cell shrinkage, however. Only a partial inhibition of 8-Br-cGMP-induced cell shrinkage is expected if the maximum level of cGMP attained by activating ANF receptors does not saturate the cGMP-dependent step. Consistent with this idea, the maximum decrease of cell volume observed with 8-Br-cGMP, 10.8%, was slightly greater than the 8.2% decrease with ANF (Fig. 1) .
Although these experiments satisfy classic criteria for identifying a second messenger, some of the results could also be explained by ANF and cGMP acting independently, in parallel on a common final target, Na+/K+/2CI-cotransport. Such a parallel scheme cannot easily explain why modulating cGMP with LY83583 and M&B22948 should have affected the efficacy of ANF as it did, however. In a parallel scheme, the effects of these agents should have been reversed from what they were.
Does Basal Production of cGMP Modulate Cell Volume?
LY83583 alone increased cell volume by 2-3% and M&B22948 alone decreased cell volume by 3%. These observations may be explained by the basal production of cGMP in the absence of stimulation of guanylate cyclase. Then, inhibition of either guanylate cyclase or cGMP-specific phosphodiesterase is expected to perturb the basal cGMP concentration, modulate Na+/K+/2CI-cotransport, and thereby adjust cell volume. In keeping with this idea, M&B22948 alone significantly elevated cGMP, but LY83583 alone did not significantly effect cGMP. We are uncertain why we were unable to detect the small decrease in cGMP expected with LY83583. One possibility is that noise introduced by the unavoidable presence of damaged myocytes in the aliquots of cells used for determining cGMP masked a small effect.
Physiological Implications
What are the physiological consequences of cell volume changes on activation of the ANF-cGMP pathway and inhibition of Na+/K+/2C1 -cotransport? We suggested previously that the decrease of cell volume induced by ANF might serve as a local mechanism for feedback inhibition ofANF release (Clemo and Baumgarten, 1991a) . In addition, one can postulate that inhibition of Na+/K+/2C1-cotransport will alter cardiac contractile function. By decreasing the influx of Na ÷, inhibition of Na+/K+/ 2C1-cotransport lowers intracellular Na + activity (Liu et al., 1987) . In turn, enhanced efflux of Ca 2+ via Na+-Ca 2+ exchange and a decrease in contractility are expected. Cell volume perturbations also may affect the interaction of the cross-bridges. Furthermore, diastolic properties may be modified. Ventricular muscle mass is an important determinant of diastolic compliance (for review, see Gaasch, Apstein, and Levine, 1985) , and by itself reduction of cell volume should increase compliance and improve cardiac filling. Preliminary studies on rabbit heart Langendorff preparations instrumented with a left ventricular balloon (Clemo and Baumgarten, 1991c ) support these predictions. Exposure to 10 /xM BUM, 10 ~xM 8-Br-cGMP, or 100 lxM SNP decreased isovolumetric systolic pressure over a wide range of left ventricular end diastolic volumes indicating a reduction in contractility (see also Meulemans, Sipido, Sys, and Brutsaert, 1988) . In addition, these agents shifted the diastolic pressurevolume curve downward and to the right, indicating an increase in ventricular compliance. Negative inotropic effects of cGMP derivatives were noted previously, and the role of cGMP in the contractile effects of muscarinic agonists has been the subject of extensive debate (Linden and Brooker, 1979; Opie, 1982; Diamond and Chu, 1985) . Our suggestion that cGMP decreases contractility in part by inhibiting Na+/K+/2C1-cotransport may be relevant in this controversy.
In summary, the present results suggest that ANF decreases cardiac cell volume via a cGMP-mediated inhibition of Na+/K +/2C1-cotransport and that the level of cGMP helps determine the volume a cell attains, cGMP is modulated physiologically by a number of mechanisms Tremblay et al., 1988) . Consequently, alteration of cardiac cell volume may be far more common than previously thought.
